All In Biotech

NDA 207561 · Gilead Sciences INC

Genvoya

Cobicistat, Elvitegravir, Emtricitabine, Tenofovir Alafenamide Fumarate · Oral · Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor; Cytochrome P450 3A Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Jan 7, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Nov 5, 2015

Approved uses

10

Original approval plus efficacy supplements

Registered trials

155

48 Phase 3, 6 recruiting

FAERS reports

10,045

7,813 serious, 199 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of GENVOYA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue GENVOYA. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or...

What it is approved for

From the label in effect Feb 3, 2025.

GENVOYA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of GENVOYA [see Clinical Studies (14) ]. GENVOYA is a four-drug combination of elvitegravir (EVG), an HIV-1 integrase strand transfer inhibitor (INSTI), cobicistat (COBI), a CYP3A inhibitor, and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of GENVOYA. ( 1 )

Mechanism: GENVOYA is a fixed-dose combination of antiretroviral drugs elvitegravir (plus the CYP3A inhibitor cobicistat), emtricitabine, and tenofovir alafenamide [see Microbiology (12.4) ] . Mechanism of Action Elvitegravir: Elvitegravir inhibits the strand transfer activity of HIV-1 integrase (integrase strand transfer inhibitor; INSTI), an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection. Elvitegravir does not inhibit...

Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • GENVOYA · COBICISTAT 150MG; ELVITEGRAVIR 150MG; EMTRICITABINE 200MG; TENOFOVIR ALAFENAMIDE FUMARATE EQ 10MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cobicistat" as an intervention, any sponsor and status, largest first.

All 155 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • bone density decreased4,545
  • chronic kidney disease2,641
  • bone loss2,432
  • osteonecrosis2,397
  • tooth loss2,280
  • multiple fractures2,144
  • renal failure2,119
  • osteoporosis1,952
  • renal injury1,931
  • pain1,867
  • emotional distress1,812
  • skeletal injury1,662

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20153
2016242
2017524
2018812
20191,136
20204,082
20211,336
2022783
2023358
2024378
2025302
202689

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Genvoya (Elviteg/Cob/Emtri/Tenof Alafen)

2024 spending

$552M

Beneficiaries

14,573

131,432 claims

Per beneficiary

$37,879

$131.85 per unit

View as table
YearSpending
2020$755,819,244
2021$701,917,029
2022$667,652,645
2023$626,148,344
2024$552,006,675

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 156 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.